Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Accelerator Corporation Creates Ninth Biotech Company - Takes Nanogen License to Create Novel Therapeutics

Abstract:
Accelerator Corporation, a privately-held biotechnology investment and development company today announced the formation of a new company, Mirina Corporation, focused on developing therapeutics using Minor Groove Binder technology to affect cellular processes involving microRNAs. Mirina, has exclusively licensed the technology from Nanogen, Inc. (NASDAQ: NGEN) for use in therapeutics and is Accelerator's first investment in a technology spinout from a publicly traded biotechnology company. The syndicate of investors leading the Series A investment in Mirina included Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Accelerator Corporation Creates Ninth Biotech Company - Takes Nanogen License to Create Novel Therapeutics

Seattle, WA | Posted on August 16th, 2008

Mirina's technology is based upon Nanogen's proprietary Minor Groove Binder technology for making novel microRNA (miRNA) therapeutics with enhanced properties. MiRNAs are a recently identified mechanism for gene regulation. Recent breakthroughs and potential applications of technologies to affect miRNAs and to use miRNA-based compounds as therapeutic agents have attracted interest from major biotechnology and pharmaceutical companies and resulted in several high-profile partnerships and mergers and acquisitions activity. By improving the properties of miRNA therapeutics, Mirina's technology presents promising potential for treating a wide range of diseases, including cancers, infectious diseases and various metabolic disorders.

Nanogen has developed and patented novel methods for preparing oligonucleotides appended with Minor Groove Binding (MGB) agents---chemical groups that have high affinity for helical DNA or RNA. This technology has been exploited by Nanogen for molecular diagnostics and has also been licensed by Applied Biosystems and ThermoFisher for research applications in Real Time PCR. By incorporating the MGB technology into miRNA therapeutics, Mirina's novel MGB-oligonucleotide compounds are anticipated to exhibit superior properties, such as enhanced target selectivity and significantly better potency.

David McElligott, Ph.D., formerly the Senior Director of Drug Discovery of ICOS, will be the Vice President of Research and Development for Mirina. During his 10 years at ICOS, Dr. McElligott coordinated the discovery and clinical entry of numerous early stage products. Prior to his ICOS employment, Dr. McElligott was an Assistant Professor at Scripps Research Institute. Collaborations with Nanogen will be overseen by Walt Mahoney, Ph.D., Vice President of Research and Development, who has led the efforts to develop the proprietary MGB technology.

"Working with Accelerator to license our technology to this new venture is an exciting new area for Nanogen," said Howard Birndorf, CEO of Nanogen, Inc. "Our MGB technology has been widely licensed for research and diagnostic applications. Extending its utility to therapeutics is in keeping with our mission to improve patient care and will provide the company with new opportunities for revenues from non-competing markets."

"Mirina is the ninth company in which we have invested at Accelerator," said Accelerator CEO Carl Weissman, "and it is the first based upon spinning technology out of an established publicly-traded biotechnology company. We are very excited to be entering the interesting area of nucleic acid-based therapeutics and believe that the Nanogen MGB technology should confer a significant advantage and differentiation to this effort."

"We continue to be impressed by Accelerator's ability to identify, evaluate and license novel and exciting proprietary technologies," said Steve Gillis, Managing Director of ARCH Venture Partners. "The field of miRNA holds great promise for treating a wide variety of diseases and we are confident that the proven MGB core technology will provide Mirina with significant advantages in this highly competitive and potentially lucrative area of therapeutic product development."

####

About Nanogen, Inc.
Nanogen, Inc., develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare.

About Accelerator Corporation

Accelerator Corporation, founded in 2003, is a privately–held biotechnology investment and development company located in Seattle, Washington, USA. The company is building the next generation of life-enhancing biotechnology companies by providing the resources critical to accelerating the development of nascent leading-edge biotechnologies. These key resources, provided by global life science leaders –Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, Alexandria Real Estate Equities, Inc., WRF Capital, and the Institute for Systems Biology - include committed capital from top-tier venture capital firms, state-of-the-art facilities, world-class scientific and technical expertise and support, and experienced biotechnology start-up business management and support. For more information, please go to: www.acceleratorcorp.com.

For more information, please click here

Contacts:
Nanogen Corporate Headquarters
10398 Pacific Center Court
San Diego, CA 92121
877-626-6436
Fax: 858-410-4952

Copyright © Nanogen, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016

Carbodeon Ltd Oy Closes EUR 1.5 million Funding Round From Straightforward Capital: Carbodeon will accelerate its nanodiamonds business and expand manufacturing capacity August 21st, 2016

Nanomedicine

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016

Announcements

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Patents/IP/Tech Transfer/Licensing

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project